Gain Therapeutics(GANX)
BETHESDA, MDBiotechnology
Focus: Gain Therapeutics is a publicly traded biotech company (NASDAQ: GANX) founded in 2023, pioneering Site-directed Enzyme Enhancement Therapy with a focus on neurology and metabolic diseases. The company is pre-revenue with minimal cash runway and an early-stage pipeline.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Total Funding
$300M
Open Jobs
17-1 this month
Stable — net -1 jobs in 30d
5 added, 6 removed. Backfill posture.
Should You Work at Gain Therapeutics?
AI assessmentGain Therapeutics is a high-risk, high-reward pre-revenue platform play suitable only for risk-tolerant scientists seeking early-stage exposure; significant dilution and cash crisis risk warrant thorough due diligence on financing runway.
Why Work Here
- Early-stage platform company with novel Site-directed Enzyme Enhancement Therapy mechanism offering opportunity to shape foundational science in neurology and metabolic disease.
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Early-stage
4 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$55K
Pipeline & Clinical Trials
Envita Stories Methodology in Long-term care Centres for old adults
Long-term Care Centres for Old Adults UsersClinical Trials (1)
NCT06569628Validation of a Life Stories Methodologies in Long-Term Care Centres
N/AHelp build intelligence for Gain Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.